尿微量清蛋白对非糖尿病ST段抬高型心肌梗死预后的预测价值

目的探讨尿微量清蛋白(MAU)对直接经皮冠状动脉介入治疗(PCI)的非糖尿病ST段抬高型心肌梗死(STEMI)患者预后的预测价值。方法110例接受直接PCI的非糖尿病STEMI患者,入院48h内行24hMAU检测,其中MAU≤20mg/24h者为MAU阴性组,MAU>20mg/24h者为MAU阳性组,观察发病后6个月～1年〔平均(10.3±3.2)个月〕时心脏事件的再发率。结果两组患者心脏事件再发率间差异有显著性意义(P<0.01);两组患者冠状动脉血管病变程度间差异有显著性意义(P<0.05);经Logistic回归分析,MAU与非糖尿病STEMI患者再发心脏事件的相对危险度(OR)为1.019,95%CI(1.005,1.033)。结论入院早期测定MAU对直接PCI治疗的非糖尿病STEMI患者的预后有预测价值,MAU增加是危险因素之一。

Predictive Value of Microalbuminuria for Prognosis of Nondiabetic ST-segment Elevation Myocardial Infarction

Objective To evaluate the prognosis capacity of the microalbuminuria for nondiabetic ST-segment elevation myocardial infarction(STEMI)treated with primary PCI.Methods 110 nondiabetic STEMI patients treated with PCI were enrolled.Urinary albumin excretion was measured with immunoturbidimet in the first 48 hours on admission.To assess the relativity with microalbuminuria and the prognostic of acute myocardial infarction patients with non-diabetic treated with primary PCI.Results The incidence of MACE was significantly different between the two groups(P<0.01).The degree of coronary artery lesion was significantly different between the two groups(P<0.05).Logistic regression analysis indicated the relative risk of MAU and nondiabetic STEMI(OR)was 1.019,95%CI(1.005,1.033).Conclusion MAU is a risk factor of patients with nondiabetic STEMI.